DexCom earnings beat by $0.03, revenue topped estimates
In a turbulent market environment, Geovax Labs Inc (GOVX) stock has touched a new 52-week low, dipping to $0.78. With a market capitalization of $14.81 million and a notably high beta of 3.71, the micro-cap biotech company shows significant sensitivity to market movements. According to InvestingPro analysis, the stock appears undervalued at current levels. This latest price level reflects a significant downturn for the biotechnology company, which has experienced a -30.07% change over the past year. While the stock has shown recent resilience with a 10.3% gain over the past week, its six-month decline of -49.29% highlights ongoing volatility. Investors have been closely monitoring Geovax Labs as it navigates through a challenging period, marked by this notable decline in stock value. The 52-week low serves as a critical indicator for the company’s performance and investor sentiment, as market participants weigh the potential for recovery against ongoing industry and economic pressures. For deeper insights into GOVX’s volatility patterns and comprehensive financial analysis, explore additional metrics on InvestingPro, where 13 more exclusive ProTips await.
In other recent news, GeoVax Labs reported a net loss of $25 million for the year 2024, with revenues reaching $4 million, primarily from a BARDA contract. The company’s significant research and development expenses rose by 14% to $23.7 million. GeoVax’s cash balance stood at $5.5 million at the end of 2024. Meanwhile, GeoVax was instructed to halt activities related to a Phase 2b clinical trial of their COVID-19 vaccine, GEO-CM04S1, following a directive from Advanced Technology International, under the funding of BARDA. This decision was made for the government’s convenience and does not reflect any performance issues with GeoVax. Additionally, there have been no updates on the future implications of this contract termination for the company. GeoVax continues to explore strategic partnerships and funding strategies to support its development programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.